RE:RE:RE:RE:ONCY's pelareorep activates TiLs (CD8+ Dendritic Cells) Overall survival data has continued to mature from the BRACELET-1 metastatic breast cancer Phase 2 study.
12 month data from this sstudyhas already validated the results of IND-213, a prior phase 2 trial that showed a statistically significant which demonstrated a near doubling of median overall survival in HR+/HER2- metastatic breast cancer patients treated with pelareorep combined with paclitaxel (21.0 months, n = 28) vs. those treated with paclitaxel alone (10.8 months, n = 29).